Skip Navigation



JAC Advance Access published online on August 18, 2004
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkh405
© 2004 by The British Society for Antimicrobial Chemotherapy
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
54/4/832    most recent
dkh405v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Spellberg, B.
Right arrow Articles by Bayer, A. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spellberg, B.
Right arrow Articles by Bayer, A. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Brief report

Reversal of linezolid-associated cytopenias, but not peripheral neuropathy, by administration of vitamin B6

Brad Spellberg 1*, Thomas Yoo 1, Arnold S. Bayer 2

1 Department of Medicine, Harbor-UCLA Research and Education Institute, 1124 West Carson St., St. John's Cardiovascular Research Center, Torrance, CA 90502, USA
2 Department of Medicine, Harbor-UCLA Research and Education Institute, 1124 West Carson St., St. John's Cardiovascular Research Center, Torrance, CA 90502, USA; David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA, USA

* To whom correspondence should be addressed. E-mail: bjs{at}humc.edu.


  Abstract

Objectives: We sought to determine if vitamin B6 therapy would reverse linezolid-associated cytopenias and/or peripheral neuropathy.

Patients and methods: We have recently treated two patients with disseminated Mycobacterium abscessus infections with prolonged (≥9 month) courses of linezolid. Both patients developed cytopenias related to linezolid, and one patient also developed peripheral neuropathy. Because continuing linezolid therapy was required, we administered vitamin B6 (50 mg orally once a day) in an attempt to mitigate the associated cytopenias.

Results: The cytopenias in both patients reversed following administration of vitamin B6, and stabilized during prolonged linezolid therapy, although the peripheral neuropathy did not.

Conclusions: Vitamin B6 treatment may be useful to prevent or modify the course of linezolid-associated cytopenias. More formal and rigorous study of vitamin B6 therapy in patients receiving prolonged courses of linezolid is warranted.

Keywords: pyridoxine; anaemia; thrombocytopenia; Mycobacteria; deficiency.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
S. Youssef, R. Hachem, R. F. Chemaly, J. Adachi, J. Ying, K. Rolston, and I. Raad
The role of vitamin B6 in the prevention of haematological toxic effects of linezolid in patients with cancer
J. Antimicrob. Chemother., February 1, 2008; 61(2): 421 - 424.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
T. Z Jodlowski, I. Melnychuk, and J. Conry
Linezolid for the Treatment of Nocardia spp. Infections
Ann. Pharmacother., October 1, 2007; 41(10): 1694 - 1699.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
A. Soriano, M. Ortega, S. Garcia, G. Penarroja, A. Bove, M. Marcos, J. C. Martinez, J. A. Martinez, and J. Mensa
Comparative Study of the Effects of Pyridoxine, Rifampin, and Renal Function on Hematological Adverse Events Induced by Linezolid
Antimicrob. Agents Chemother., July 1, 2007; 51(7): 2559 - 2563.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
G. Garrabou, A. Soriano, S. Lopez, J. P. Guallar, M. Giralt, F. Villarroya, J. A. Martinez, J. Casademont, F. Cardellach, J. Mensa, et al.
Reversible Inhibition of Mitochondrial Protein Synthesis during Linezolid-Related Hyperlactatemia
Antimicrob. Agents Chemother., March 1, 2007; 51(3): 962 - 967.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
R. N. Jones, J. E. Ross, T. R. Fritsche, and H. S. Sader
Oxazolidinone susceptibility patterns in 2004: report from the Zyvox(R) Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations
J. Antimicrob. Chemother., February 1, 2006; 57(2): 279 - 287.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
J. Fortun, P. Martin-Davila, E. Navas, M. J. Perez-Elias, J. Cobo, M. Tato, E. G.-G. De la Pedrosa, E. Gomez-Mampaso, and S. Moreno
Linezolid for the treatment of multidrug-resistant tuberculosis
J. Antimicrob. Chemother., July 1, 2005; 56(1): 180 - 185.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
S. A. Zivkovic and D. Lacomis
Severe sensory neuropathy associated with long-term linezolid use
Neurology, March 8, 2005; 64(5): 926 - 927.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.